GlobeNewswire Inc.··NaCardiff Oncology to Present Onvansertib Phase 2 Data at ASCO 2026
Cardiff Oncology will present updated Phase 2 data for onvansertib in RAS-mutated colorectal cancer at ASCO 2026 in June.
CRDFcolorectal cancerphase 2 trial
C
$CRDF
2 articles found2 positive
0 negative
0 neutral
GlobeNewswire Inc.··NaGlobeNewswire Inc.··NaCardiff Oncology's Onvansertib Shows Promise in Overcoming HER2-Low Breast Cancer Resistance
Cardiff Oncology's onvansertib shows preclinical promise in reversing HER2-low breast cancer resistance when combined with trastuzumab deruxtecan; data presentation scheduled for April 2026.
CRDFmetastatic colorectal cancerAACR Annual Meeting 2026